Case study of development, validation, and acceptance of a non-animal method for assessing veterinary vaccine potency

Procedia in Vaccinology

Volumn 5, Issue , 2011, Pages 175-183

  Claassen, Ivo ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Acceptance; Non animal method; Validation; Veterinary vaccine potency testing

Indexed keywords

HN PROTEIN; INACTIVATED VIRUS VACCINE; MINERAL OIL; NEWCASTLE DISEASE VACCINE; WATER OIL CREAM;

ANTIBODY SPECIFICITY; ARTICLE; CASE STUDY; DRUG APPROVAL; DRUG DESIGN; DRUG DETERMINATION; DRUG FORMULATION; DRUG INDUSTRY; DRUG ISOLATION; DRUG MANUFACTURE; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTINATION INHIBITION; IMMUNE RESPONSE; IN VIVO STUDY; MEDICAL LITERATURE; NEWCASTLE DISEASE; PRIORITY JOURNAL; VACCINATION; VALIDATION STUDY; VIRUS NEUTRALIZATION;

EID: 84555217940     PISSN: None     EISSN: 1877282X     Source Type: Journal    
DOI: 10.1016/j.provac.2011.10.017     Document Type: Article

References (18)

1. Hendriksen C.F., Replacement reduction and refinement alternatives to animal use in vaccine potency measurement. Expert Rev Vaccines 2009, 8(3):313-322.
2. Hendriksen C., Speiser J.-M., Akkermans A., Balls M., Bruckner L., Cussler K., et al. Validation of alternative methods for the potency testing of vaccines: the report and recommendations of ECVAM Workshop 31. ATLA 1998, 26:747-761.
3. Maas R.A., Oei H.L., Venema-Kemper S., Koch G., Bongers J. Dose-response effects of inactivated Newcastle disease vaccines: influence of serologic assay, time after vaccination, and type of chickens. Avian Dis 1999, 43(4):670-677.
4. Liljebjelke K.A., King D.J., Kapczynski D.R. Determination of minimum hemagglutinin units in an inactivated Newcastle disease virus vaccine for clinical protection of chickens from exotic Newcastle disease virus challenge. Avian Dis 2008, 52:260-268.
5. European Pharmacopoeia, 5th ed. Monograph 01/2007:0870. Strasbourg, France: European Department for the Quality of Medicines & HealthCare (EDQM), Council of Europe, 2007.
6. Stone H.D. Determination of hemagglutination activity recovered from oil-emulsion Newcastle disease vaccines as a prediction of efficacy. Avian Dis 1985, 29(3):721-728.
7. Maas R.A., Komen M., van Diepen M., Oei H.L., Claassen I.J. Correlation of haemagglutinin-neuraminidase and fusion protein content with protective antibody response after immunisation with inactivated Newcastle disease vaccines. Vaccine 2003, 21(23):3137-3142.
8. Reynolds D.L., Maraqa A.D. Protective immunity against Newcastle disease: the role of antibodies specific to Newcastle disease virus polypeptides. Avian Dis 2000, 44(1):138-144.
9. Maas R.A., de Winter M.P., Venema S., Oei H.L., Claassen I.J. Antigen quantification as in vitro alternative for potency testing of inactivated viral poultry vaccines. Vet Q 2000, 22(4):223-227.
10. Claassen I, Maas R, Oei H, Daas A, Milne C. Validation study to evaluate the reproducibility of a candidate in vitro potency assay of Newcastle disease vaccines and to establish the suitability of a candidate biological reference preparation. Pharmeuropa Bio 2004;Dec(1):1-15.
11. Maas R., Komen M., Oei H., Claassen I. Validation of a candidate in vitro potency assay for inactivated Newcastle disease vaccines. Dev Biol (Basel) 2002, 111:163-169.
12. Claassen I, Maas R, Daas A, Milne C. Feasibility study to evaluate the correlation between results of a candidate in vitro assay and established in vivo assays for potency determination of Newcastle disease vaccines. Pharmeuropa Bio 2003;Jul(1):51-66.
13. Maas R., van Diepen M., Komen M., Oei H., Claassen I. Antigen content of inactivated Newcastle disease oil emulsion vaccines as an in vitro indicator of potency. Dev Biol (Basel) 2002, 111:313-318.
14. International Cooperation on Harmonisation of Technical Registration of Veterinary Medicinal Products/Veterinary International Conference on Harmonisation (VICH). VICH GL1, Validation of Analytical Procedures: Definition and Terminology. Brussels, Belgium: VICH, 1998 (implemented 1999). Available at: http://www.vichsec.org/pdf/gl01_st7.pdf.
15. International Cooperation on Harmonisation of Technical Registration of Veterinary Medicinal Products/Veterinary International Conference on Harmonisation (VICH). VICH GL2, Validation of Analytical Procedures: Methodology. Brussels, Belgium: VICH, 1998 (implemented 1999). Available at: http://www.vichsec.org/pdf/gl02_st7.pdf.
16. International Cooperation on Harmonisation of Technical Registration of Veterinary Medicinal Products/Veterinary International Conference on Harmonisation (VICH). VICH GL17, Stability Testing of New Biotechnological /Biological Veterinary Medicinal Products. Brussels, Belgium: VICH, 2000 (implemented 2001). Available at: http://www.vichsec.org/pdf/2000/Gl17_st7.pdf.
17. Oei H., Maas R., Venema S., Kant A., Claassen I. Quantification of infectious bursal disease viral proteins 2 and 3 in inactivated vaccines as an indicator of serological response and measure of potency. Avian Pathol 2004, 33(2):126-132.
18. Jagt H.J., Bekkers M.L., van Bommel S.A., van der Marel P., Schrier C.C. The influence of the inactivating agent on the antigen content of inactivated Newcastle disease vaccines assessed by the in vitro potency test. Biologicals 2010, 38(1):128-134.